Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL

Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma

Choosing Wisely: Managing resectable colorectal liver metastases

Optimal management of gastric cancers

Do all hormone sensitive prostate cancers need triplet therapy?

Choosing Wisely: ctDNA/ Precision Oncology in colorectal cancers

ESMO 2025: Precision medicine in bladder cancer

Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC

ESMO 2025: Highlights and analysis

Best practice in precision medicine for prostate cancer

Neoadjuvant TAR-200 plus cetrelimab improves PCR in muscle-invasive bladder cancer